https://www.selleckchem.com/pr....oducts/pyridostatin-
of insulin secretagogues, since such patients have the potential to successfully withdraw from basal insulin use even in an outpatient setting. This study aimed to investigate the generalizability of the results of cardiovascular outcome trials (CVOTs) of glucagon-like peptide1 receptor agonists (GLP-1RAs) to Chinese patients with type2 diabetes mellitus (T2DM). The 3B (Blood Glucose, Blood Pressure, and Blood Lipid) population, a nationally representative population of patients with T2DM in China (n = 25,411)
Like
Comment
Share
